Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib cream for discoid lupus erythematosus
NCT04908280Phase 2Completed
- Sponsor
- University of Rochester
- Start
- May 2022
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib cream in discoid lupus erythematosus (DLE), sponsored by University of Rochester. Primary endpoint: Investigator's Global Assessment at 12 weeks. Started May 2022; status: completed.
02
Drugs
ruxolitinib cream
03
Conditions
discoid lupus erythematosus (DLE)
Beyond the preview
Go deeper on NCT04908280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04908280.